tiprankstipranks
Tenax Therapeutics (TENX)
NASDAQ:TENX
US Market
TENX
Tenax Therapeutics
RESEARCH TOOLSreports
Want to see TENX full AI Analyst Report?

Tenax Therapeutics (TENX) Stock Forecast & Price Target

670 Followers
See the Price Targets and Ratings of:

TENX Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Tenax
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TENX Stock 12 Month Forecast

Average Price Target

$37.40
▲(158.82% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Tenax Therapeutics in the last 3 months. The average price target is $37.40 with a high forecast of $50.00 and a low forecast of $27.00. The average price target represents a 158.82% change from the last price of $14.45.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","51":"$51","15.75":"$15.75","27.5":"$27.5","39.25":"$39.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,15.75,27.5,39.25,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.29,16.113846153846154,18.93769230769231,21.76153846153846,24.585384615384616,27.40923076923077,30.233076923076922,33.05692307692308,35.88076923076923,38.70461538461539,41.52846153846154,44.35230769230769,47.176153846153845,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.29,15.144615384615383,16.999230769230767,18.853846153846153,20.70846153846154,22.56307692307692,24.417692307692306,26.27230769230769,28.126923076923077,29.98153846153846,31.836153846153845,33.690769230769234,35.54538461538461,{"y":37.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.29,14.344615384615384,15.399230769230769,16.453846153846154,17.50846153846154,18.563076923076924,19.61769230769231,20.67230769230769,21.72692307692308,22.78153846153846,23.83615384615385,24.89076923076923,25.945384615384615,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.34,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.19,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.62,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.97,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.29,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$37.40Lowest Price Target$27.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on TENX
Gaurav Maini
LifeSci Capital
LifeSci Capital
$27→$35
Buy
142.21%
Upside
Reiterated
07/06/26
LifeSci Capital Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)
Cantor Fitzgerald Analyst forecast on TENX
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$35
Buy
142.21%
Upside
Reiterated
06/24/26
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX), Biohaven Ltd. (NYSE: BHVN) and BioLife Solutions (NASDAQ: BLFS)
Chardan Capital Analyst forecast on TENX
Unknown Analyst
Chardan Capital
Not Ranked
Chardan Capital
$27
Buy
86.85%
Upside
Initiated
06/22/26
Tenax Therapeutics initiated with a Buy at ChardanTenax Therapeutics initiated with a Buy at Chardan
Guggenheim Analyst forecast on TENX
Seamus Fernandez
Guggenheim
Guggenheim
$34→$40
Buy
176.82%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX), Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV)
Piper Sandler Analyst forecast on TENX
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$20→$50
Buy
246.02%
Upside
Reiterated
06/12/26
Tenax Therapeutics price target raised to $50 from $20 at Piper SandlerTenax Therapeutics price target raised to $50 from $20 at Piper Sandler
William Blair Analyst forecast on TENX
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX) and Acurx Pharmaceuticals (NASDAQ: ACXP)
Roth MKM Analyst forecast on TENX
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$30
Buy
107.61%
Upside
Reiterated
03/11/26
Roth MKM Keeps Their Buy Rating on Tenax Therapeutics (TENX)
Leerink Partners Analyst forecast on TENX
David Risinger
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
09/17/25
Tenax Therapeutics (TENX) Gets a Buy from Leerink Partners
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on TENX
Gaurav Maini
LifeSci Capital
LifeSci Capital
$27→$35
Buy
142.21%
Upside
Reiterated
07/06/26
LifeSci Capital Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)
Cantor Fitzgerald Analyst forecast on TENX
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$35
Buy
142.21%
Upside
Reiterated
06/24/26
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX), Biohaven Ltd. (NYSE: BHVN) and BioLife Solutions (NASDAQ: BLFS)
Chardan Capital Analyst forecast on TENX
Unknown Analyst
Chardan Capital
Not Ranked
Chardan Capital
$27
Buy
86.85%
Upside
Initiated
06/22/26
Tenax Therapeutics initiated with a Buy at ChardanTenax Therapeutics initiated with a Buy at Chardan
Guggenheim Analyst forecast on TENX
Seamus Fernandez
Guggenheim
Guggenheim
$34→$40
Buy
176.82%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX), Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV)
Piper Sandler Analyst forecast on TENX
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$20→$50
Buy
246.02%
Upside
Reiterated
06/12/26
Tenax Therapeutics price target raised to $50 from $20 at Piper SandlerTenax Therapeutics price target raised to $50 from $20 at Piper Sandler
William Blair Analyst forecast on TENX
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX) and Acurx Pharmaceuticals (NASDAQ: ACXP)
Roth MKM Analyst forecast on TENX
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$30
Buy
107.61%
Upside
Reiterated
03/11/26
Roth MKM Keeps Their Buy Rating on Tenax Therapeutics (TENX)
Leerink Partners Analyst forecast on TENX
David Risinger
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
09/17/25
Tenax Therapeutics (TENX) Gets a Buy from Leerink Partners
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tenax Therapeutics

3 Months
Seamus FernandezGuggenheim
Success Rate
5/6 ratings generated profit
83%
Average Return
+21.02%
Copying Seamus Fernandez's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +21.02% per trade.
1 Year
David RisingerLeerink Partners
Success Rate
8/8 ratings generated profit
100%
Average Return
+125.95%
Copying David Risinger's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +125.95% per trade.
2 Years
David RisingerLeerink Partners
Success Rate
8/8 ratings generated profit
100%
Average Return
+169.14%
Copying David Risinger's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +169.14% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TENX Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
5
5
9
9
10
Buy
1
5
6
5
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
10
15
14
11
In the current month, TENX has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TENX average Analyst price target in the past 3 months is 37.40.
Each month's total comprises the sum of three months' worth of ratings.

TENX Financial Forecast

TENX Earnings Forecast

Next quarter’s earnings estimate for TENX is -$0.38 with a range of -$0.45 to -$0.31. The previous quarter’s EPS was -$0.35. TENX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TENX has Performed in-line its overall industry.
Next quarter’s earnings estimate for TENX is -$0.38 with a range of -$0.45 to -$0.31. The previous quarter’s EPS was -$0.35. TENX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TENX has Performed in-line its overall industry.
No data currently available

TENX Sales Forecast

Next quarter’s sales forecast for TENX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TENX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TENX has Performed in-line its overall industry.
Next quarter’s sales forecast for TENX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TENX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TENX has Performed in-line its overall industry.

TENX Stock Forecast FAQ

What is TENX’s average 12-month price target, according to analysts?
Based on analyst ratings, Tenax Therapeutics’s 12-month average price target is 37.40.
    What is TENX’s upside potential, based on the analysts’ average price target?
    Tenax Therapeutics has 158.82% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TENX a Buy, Sell or Hold?
          Tenax Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Tenax Therapeutics’s price target?
            The average price target for Tenax Therapeutics is 37.40. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $50.00 ,the lowest forecast is $27.00. The average price target represents 158.82% Increase from the current price of $14.45.
              What do analysts say about Tenax Therapeutics?
              Tenax Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of TENX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.